ArticleCase reports in oncological medicine2026
Observed Immune Response Following Histotripsy in Metastatic Hepatocellular Carcinoma.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observed Immune Response Following Histotripsy in Metastatic Hepatocellular Carcinoma.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Histotripsy is a novel, noninvasive, nonthermal tumor ablation therapy that uses focused ultrasound to mechanically disrupt tissue. Emerging evidence suggests that histotripsy may stimulate antitumor immune responses. To our knowledge, this is one of the first reported cases of histotripsy used in conjunction with systemic immunotherapy in a patient with hepatocellular carcinoma (HCC), resulting in an observed systemic immune response in nontarget lesions. Case Presentation: A 63-year-old male with noncirrhotic, nonviral multifocal metastatic HCC was treated with combination systemic immunotherapy (atezolizumab plus bevacizumab), followed by targeted histotripsy ablation of hepatic Segment II lesions. Given the presence of extrahepatic metastatic disease, liver transplantation was not a viable option. Posthistotripsy imaging demonstrated a partial response in the targeted lesion but partial responses in multiple nontarget lesions. This radiographic response occurred after discontinuation of systemic therapy due to toxicity. The patient maintained excellent functional status and continues to undergo histotripsy treatment. Conclusion: This case highlights the potential for histotripsy to elicit an abscopal-like immune response in metastatic HCC when combined with immunotherapy. Histotripsy may serve as a valuable adjunct to systemic therapy, particularly in patients unable to tolerate prolonged immunotherapy. Further studies are warranted to explore this potential synergy in controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.